CTLA-4 and CD86 genetic variants and haplotypes in patients with rheumatoid arthritis in southeastern China

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1373-1382

  Liu, C P ^a   Jiang, J A ^a,b   Wang, T ^b   Liu, X M ^c   Gao, L ^b   Zhu, R R ^b   Shen, Y ^a   Wu, M ^d   Xu, T ^d   Zhang, X G ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c Suzhou Health Technology College   (China)

^d THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

CD86; CTLA 4; Rheumatoid arthritis; Single nucleotide polymorphisms

Indexed keywords

CD86 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; RHEUMATOID FACTOR;

ADULT; ARTICLE; CD86 GENE; CHINESE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 GENE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876818789     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.April.25.8     Document Type: Article

References (32)

1. Abdallah AM, Renzoni EA, Anevlavis S, Lagan AL, et al. (2006). A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis. Int. J. Immunogenet. 33: 155-161.
2. Almasi S, Erfani N, Mojtahedi Z, Rajaee A, et al. (2006). Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun. 7: 401-406.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
4. Catalan D, Aravena O, Sabugo F, Wurmann P, et al. (2010). B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12: R68.
5. Chang JC, Liu CA, Chuang H, Ou CY, et al. (2004). Gender-limited association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphism with cord blood IgE levels. Pediatr. Allergy Immunol. 15: 506-512.
6. Fox D (2005). Etiology and Pathogenesis of Rheumatoid Arthritis. In: Arthritis and Allied Conditions (Koopman W, ed.). Lippincott Williams & Wilkins, Philadephia, 1089-1115.
7. Haimila K, Einarsdottir E, de Kauwe A, Koskinen LL, et al. (2009). The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and common variable immunodeficiency. Genes Immun. 10: 151-161.
8. Howson JM, Walker NM, Smyth DJ and Todd JA (2009). Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun. 10 (Suppl 1): S74-S84.
9. Jones AL, Holliday EG, Mowry BJ, McLean DE, et al. (2009). CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain Behav. Immun. 23: 347-350.
10. Kouki T, Gardine CA, Yanagawa T and Degroot LJ (2002). Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J. Endocrinol. Invest. 25: 208-213.
11. Kusztal M, Kościelska-Kasprzak K, Drulis-Fajdasz D, Magott-Procelewska M, et al. (2010). The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. Transpl. Immunol. 23: 121-124.
12. Landi D, Moreno V, Guino E, Vodicka P, et al. (2011). Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat. Res. 717: 109-115.
13. Liang YL, Wu H, Li PQ, Xie XD, et al. (2011). Signal transducer and activator of transcription 4 gene polymorphisms associated with rheumatoid arthritis in Northwestern Chinese Han population. Life Sci. 89: 171-175.
14. Ligers A, Teleshova N, Masterman T, Huang WX, et al. (2001). CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2: 145-152.
15. Liu MF, Kohsaka H, Sakurai H, Azuma M, et al. (1996). The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum. 39: 110-114.
16. Liu Y, Liang WB, Gao LB, Pan XM, et al. (2010). CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Hum. Immunol. 71: 1141-1146.
17. Magistrelli G, Jeannin P, Herbault N, Benoit De CA, et al. (1999). A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29: 3596-3602.
18. Marin LA, Moya-Quiles MR, Miras M, Muro M, et al. (2005). Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl. Immunol. 15: 69-74.
19. Matsushita M, Tsuchiya N, Oka T, Yamane A, et al. (2000). New polymorphisms of human CD80 and CD86: lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun. 1: 428-434.
20. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, et al. (2002). A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54: 1-8.
21. Orozco G, Rueda B and Martin J (2006). Genetic basis of rheumatoid arthritis. Biomed. Pharmacother. 60: 656-662.
22. Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, et al. (2010). Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum. Immunol. 71: 195-200.
23. Plant D, Flynn E, Mbarek H, Dieude P, et al. (2010). Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann. Rheum. Dis. 69: 1548-1553.
24. Rai E and Wakeland EK (2011). Genetic predisposition to autoimmunity-what have we learned? Semin. Immunol. 23: 67-83.
25. Scalapino KJ and Daikh DI (2008). CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 223: 143-155.
26. Sharpe AH and Freeman GJ (2002). The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126.
27. Sole X, Guino E, Valls J, Iniesta R, et al. (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929.
28. Su TH, Chang TY, Lee YJ, Chen CK, et al. (2007). CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 28: 1237-1240.
29. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, et al. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
30. Wang XB, Zhao X, Giscombe R and Lefvert AK (2002). A CTLA-4 gene polymorphism at position-318 in the promoter region affects the expression of protein. Genes Immun. 3: 233-234.
31. Yadav D and Sarvetnick N (2007). B7-2 regulates survival, phenotype, and function of APCs. J. Immunol. 178: 6236-6241.
32. Zaletel K, Krhin B, Gaberscek S and Hojker S (2006). Thyroid autoantibody production is influenced by exon 1 and promoter CTLA-4 polymorphisms in patients with Hashimoto's thyroiditis. Int. J. Immunogenet. 33: 87-91.